MX2023004020A - Anticuerpos anti-ngf y métodos para su uso. - Google Patents

Anticuerpos anti-ngf y métodos para su uso.

Info

Publication number
MX2023004020A
MX2023004020A MX2023004020A MX2023004020A MX2023004020A MX 2023004020 A MX2023004020 A MX 2023004020A MX 2023004020 A MX2023004020 A MX 2023004020A MX 2023004020 A MX2023004020 A MX 2023004020A MX 2023004020 A MX2023004020 A MX 2023004020A
Authority
MX
Mexico
Prior art keywords
methods
ngf antibodies
antibodies
ngf
antigen binding
Prior art date
Application number
MX2023004020A
Other languages
English (en)
Inventor
Lisa Marie Bergeron
Gary F Bammert
Catherine J Strietzel
Graeme Bainbridge
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2023004020A publication Critical patent/MX2023004020A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción comprende anticuerpos anti-NGF novedosos, proteínas de unión a antígenos y polinucleótidos que las codifican. La descripción también prevé el uso de los anticuerpos, nucleótidos y/o proteínas de unión a antígenos novedosos de la invención para el tratamiento y/o la prevención de trastornos relacionados con NGF, particularmente, para el manejo del dolor.
MX2023004020A 2020-10-07 2021-10-07 Anticuerpos anti-ngf y métodos para su uso. MX2023004020A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063088729P 2020-10-07 2020-10-07
PCT/US2021/054009 WO2022076712A2 (en) 2020-10-07 2021-10-07 Anti-ngf antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023004020A true MX2023004020A (es) 2023-07-07

Family

ID=78483551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004020A MX2023004020A (es) 2020-10-07 2021-10-07 Anticuerpos anti-ngf y métodos para su uso.

Country Status (9)

Country Link
US (1) US20220106391A1 (es)
EP (1) EP4225788A2 (es)
JP (1) JP2023544839A (es)
KR (1) KR20230104157A (es)
CN (1) CN116568708A (es)
AU (1) AU2021358987A1 (es)
CA (1) CA3198362A1 (es)
MX (1) MX2023004020A (es)
WO (1) WO2022076712A2 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1982E (fr) 1903-06-15 1903-11-24 Etienne Mares Doseur d'air dans les carburateurs de moteurs à essence ou à pétrole
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
BR0009074A (pt) 1999-03-18 2002-01-02 Merck Patent Gmbh Proteìna para bloquear adesão de plaqueta
EP1130098A3 (en) 2000-02-29 2003-09-10 Pfizer Products Inc. Mammalian osteoregulins
EP2340849A1 (en) 2001-05-30 2011-07-06 Genentech, Inc. Anti-NGF antibodies for the treatment of various disorders
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
CA2469833C (en) 2001-12-21 2008-05-20 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
RS63063B1 (sr) * 2010-08-19 2022-04-29 Zoetis Belgium S A Anti-ngf antitela i njihova upotreba
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
CN104364264B (zh) * 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
EP3765499A1 (en) * 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf antibodies and methods thereof

Also Published As

Publication number Publication date
AU2021358987A1 (en) 2023-05-11
KR20230104157A (ko) 2023-07-07
WO2022076712A3 (en) 2022-05-12
US20220106391A1 (en) 2022-04-07
WO2022076712A2 (en) 2022-04-14
CA3198362A1 (en) 2022-04-14
CN116568708A (zh) 2023-08-08
JP2023544839A (ja) 2023-10-25
EP4225788A2 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
PH12020500643A1 (en) Anti-ngf antibodies and methods thereof
PH12020551211A1 (en) Antibodies binding to gprc5d
CR20220019A (es) Anticuerpos que se fijan a gprc5d
MY194642A (en) Antibodies binding to cd3
MX2021003548A (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
TW200745163A (en) Peptides that block the binding of IgG to FcRn
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
MX2017010919A (es) Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
MX2021010877A (es) Moleculas de union a cumulo de diferenciacion 3 (cd3).
WO2005099755A3 (en) Methods of treating autoimmune and inflammatory diseases
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2020011498A (es) Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas.
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2022015609A (es) ANTICUERPOS ANTI-TGFß Y USOS TERAPÉUTICOS DE ESTOS.
MX2023004020A (es) Anticuerpos anti-ngf y métodos para su uso.
MX2022000988A (es) Proteinas de union a antigeno anti-il13.